Skip to main content
PMC home page
Molecular Medicine logoLink to Molecular Medicine
. 1999 Jan;5(1):11–20.

Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions.

J M Kirkwood 1, D L Farkas 1, A Chakraborty 1, K F Dyer 1, D J Tweardy 1, J L Abernethy 1, H D Edington 1, S S Donnelly 1, D Becker 1
PMCID: PMC2230371  PMID: 10072444

Abstract

BACKGROUND: In the setting of familial melanoma, the presence of atypical nevi, which are the precursors of melanoma, is associated with a nearly 100% risk of developing primary melanoma by age 70. In patients with sporadic melanoma, it is estimated that 40-60% of melanomas develop in contiguous association with atypical nevi. Currently, the only way to prevent atypical nevi from progressing to melanoma is to monitor and excise them as soon as they exhibit changes in their clinical features. Activation of the transcription factor, Stat3, has been linked to abnormal cell growth and transformation as well as to interferon alpha (IFN-alpha)-mediated growth suppression in vitro. MATERIALS AND METHODS: To determine whether IFN-alpha, used for adjuvant therapy of high-risk, resected melanoma, induces changes in Stat3 in atypical nevi, patients with a clinical history of melanoma who have multiple atypical nevi were treated for 3 months with low-dose IFN-alpha. Thereupon, the new technology of microscopic spectral imaging and biochemical assays such as electrophoretic mobility shift assays (EMSAs) and immunoblot analysis were used for the study of atypical nevi, obtained before and after IFN-alpha treatment. RESULTS: The results of the investigations provided evidence that, as a result of systemic IFN-alpha treatment, Stat1 and Stat3, which are constitutively activated in melanoma precursor lesions, lose their ability to bind DNA, and as shown in the case of Stat3, become dephosphorylated. CONCLUSIONS: Unlike primary and metastatic melanomas, melanoma precursor lesions cannot be established as cell cultures. Thus, the only way to explore pathways and treatment regimens that might help prevent progression to melanoma is within the context of a melanoma precursor lesion study conducted prospectively. The findings presented here suggest that down-regulation of the transcription factors Stat1 and Stat3 by systemic IFN-alpha treatment may represent a potential pathway to prevent the activation of gene(s) whose expression may be required for atypical nevus cells to progress to melanoma.

Full text

PDF
11

Images in this article

14Fig. 1
on p.14
16Fig. 2
on p.16
17Fig. 3
on p.17

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chakraborty A., White S. M., Schaefer T. S., Ball E. D., Dyer K. F., Tweardy D. J. Granulocyte colony-stimulating factor activation of Stat3 alpha and Stat3 beta in immature normal and leukemic human myeloid cells. Blood. 1996 Oct 1;88(7):2442–2449. [PubMed] [Google Scholar]
  2. Chung C. D., Liao J., Liu B., Rao X., Jay P., Berta P., Shuai K. Specific inhibition of Stat3 signal transduction by PIAS3. Science. 1997 Dec 5;278(5344):1803–1805. doi: 10.1126/science.278.5344.1803. [DOI] [PubMed] [Google Scholar]
  3. Darnell J. E., Jr, Kerr I. M., Stark G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994 Jun 3;264(5164):1415–1421. doi: 10.1126/science.8197455. [DOI] [PubMed] [Google Scholar]
  4. Darnell J. E., Jr STATs and gene regulation. Science. 1997 Sep 12;277(5332):1630–1635. doi: 10.1126/science.277.5332.1630. [DOI] [PubMed] [Google Scholar]
  5. David M., Grimley P. M., Finbloom D. S., Larner A. C. A nuclear tyrosine phosphatase downregulates interferon-induced gene expression. Mol Cell Biol. 1993 Dec;13(12):7515–7521. doi: 10.1128/mcb.13.12.7515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Elder D. E., Clark W. H., Jr, Elenitsas R., Guerry D., 4th, Halpern A. C. The early and intermediate precursor lesions of tumor progression in the melanocytic system: common acquired nevi and atypical (dysplastic) nevi. Semin Diagn Pathol. 1993 Feb;10(1):18–35. [PubMed] [Google Scholar]
  7. Farkas D. L., Du C., Fisher G. W., Lau C., Niu W., Wachman E. S., Levenson R. M. Non-invasive image acquisition and advanced processing in optical bioimaging. Comput Med Imaging Graph. 1998 Mar-Apr;22(2):89–102. doi: 10.1016/s0895-6111(98)00011-1. [DOI] [PubMed] [Google Scholar]
  8. Fukada T., Hibi M., Yamanaka Y., Takahashi-Tezuka M., Fujitani Y., Yamaguchi T., Nakajima K., Hirano T. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity. 1996 Nov;5(5):449–460. doi: 10.1016/s1074-7613(00)80501-4. [DOI] [PubMed] [Google Scholar]
  9. Grob J. J., Dreno B., de la Salmonière P., Delaunay M., Cupissol D., Guillot B., Souteyrand P., Sassolas B., Cesarini J. P., Lionnet S. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet. 1998 Jun 27;351(9120):1905–1910. doi: 10.1016/s0140-6736(97)12445-x. [DOI] [PubMed] [Google Scholar]
  10. Haspel R. L., Salditt-Georgieff M., Darnell J. E., Jr The rapid inactivation of nuclear tyrosine phosphorylated Stat1 depends upon a protein tyrosine phosphatase. EMBO J. 1996 Nov 15;15(22):6262–6268. [PMC free article] [PubMed] [Google Scholar]
  11. Hou J., Schindler U., Henzel W. J., Ho T. C., Brasseur M., McKnight S. L. An interleukin-4-induced transcription factor: IL-4 Stat. Science. 1994 Sep 16;265(5179):1701–1706. doi: 10.1126/science.8085155. [DOI] [PubMed] [Google Scholar]
  12. Ihara S., Nakajima K., Fukada T., Hibi M., Nagata S., Hirano T., Fukui Y. Dual control of neurite outgrowth by STAT3 and MAP kinase in PC12 cells stimulated with interleukin-6. EMBO J. 1997 Sep 1;16(17):5345–5352. doi: 10.1093/emboj/16.17.5345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ihle J. N. STATs: signal transducers and activators of transcription. Cell. 1996 Feb 9;84(3):331–334. doi: 10.1016/s0092-8674(00)81277-5. [DOI] [PubMed] [Google Scholar]
  14. Kirkwood J. M., Strawderman M. H., Ernstoff M. S., Smith T. J., Borden E. C., Blum R. H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996 Jan;14(1):7–17. doi: 10.1200/JCO.1996.14.1.7. [DOI] [PubMed] [Google Scholar]
  15. Leaman D. W., Leung S., Li X., Stark G. R. Regulation of STAT-dependent pathways by growth factors and cytokines. FASEB J. 1996 Dec;10(14):1578–1588. [PubMed] [Google Scholar]
  16. Liu B., Liao J., Rao X., Kushner S. A., Chung C. D., Chang D. D., Shuai K. Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10626–10631. doi: 10.1073/pnas.95.18.10626. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Migone T. S., Lin J. X., Cereseto A., Mulloy J. C., O'Shea J. J., Franchini G., Leonard W. J. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science. 1995 Jul 7;269(5220):79–81. doi: 10.1126/science.7604283. [DOI] [PubMed] [Google Scholar]
  18. Minami M., Inoue M., Wei S., Takeda K., Matsumoto M., Kishimoto T., Akira S. STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3963–3966. doi: 10.1073/pnas.93.9.3963. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Pehamberger H., Soyer H. P., Steiner A., Kofler R., Binder M., Mischer P., Pachinger W., Auböck J., Fritsch P., Kerl H. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol. 1998 Apr;16(4):1425–1429. doi: 10.1200/JCO.1998.16.4.1425. [DOI] [PubMed] [Google Scholar]
  20. Sadowski H. B., Shuai K., Darnell J. E., Jr, Gilman M. Z. A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science. 1993 Sep 24;261(5129):1739–1744. doi: 10.1126/science.8397445. [DOI] [PubMed] [Google Scholar]
  21. Schindler C., Darnell J. E., Jr Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem. 1995;64:621–651. doi: 10.1146/annurev.bi.64.070195.003201. [DOI] [PubMed] [Google Scholar]
  22. Tweardy D. J., Wright T. M., Ziegler S. F., Baumann H., Chakraborty A., White S. M., Dyer K. F., Rubin K. A. Granulocyte colony-stimulating factor rapidly activates a distinct STAT-like protein in normal myeloid cells. Blood. 1995 Dec 15;86(12):4409–4416. [PubMed] [Google Scholar]
  23. Wang Y., Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med. 1997 Aug;3(8):887–893. doi: 10.1038/nm0897-887. [DOI] [PubMed] [Google Scholar]
  24. Wang Y., Rao U., Mascari R., Richards T. J., Panson A. J., Edington H. D., Shipe-Spotloe J. M., Donnelly S. S., Kirkwood J. M., Becker D. Molecular analysis of melanoma precursor lesions. Cell Growth Differ. 1996 Dec;7(12):1733–1740. [PubMed] [Google Scholar]
  25. Wong P., Severns C. W., Guyer N. B., Wright T. M. A unique palindromic element mediates gamma interferon induction of mig gene expression. Mol Cell Biol. 1994 Feb;14(2):914–922. doi: 10.1128/mcb.14.2.914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Yu C. L., Meyer D. J., Campbell G. S., Larner A. C., Carter-Su C., Schwartz J., Jove R. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science. 1995 Jul 7;269(5220):81–83. doi: 10.1126/science.7541555. [DOI] [PubMed] [Google Scholar]

Articles from Molecular Medicine are provided here courtesy of The Feinstein Institute for Medical Research at North Shore LIJ

RESOURCES